Alpivab
peramivir
Table of contents
Overview
The marketing authorisation for Alpivab has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Alpivab
|
| Agency product number |
EMEA/H/C/004299
|
| Active substance |
Peramivir
|
| International non-proprietary name (INN) or common name |
peramivir
|
| Therapeutic area (MeSH) |
Influenza, Human
|
| Anatomical therapeutic chemical (ATC) code |
J05AH03
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Biocryst
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
13/04/2018
|
| Contact address |
Biocryst |
Product information
20/11/2020 Alpivab - EMEA/H/C/004299 - T/0004
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.